文献速递脊柱外科小儿骨科骨质疏松与代谢性骨病

性早熟是脊柱侧凸的重要风险因素:GnRHa治疗协同效应与维生素D保护作用的回顾性队列研究

Precocious Puberty as a Significant Risk Factor for Scoliosis: A Retrospective Cohort Study Demonstrating Synergistic Effects of GnRHa Therapy and Protective Role of Vitamin D.
PubMed 文献 · Spine (Phila Pa 1976) · 2026-04-02

该研究通过横断面(5605人)和回顾性队列(1575人)分析发现,性早熟患者脊柱侧凸患病率显著高于对照组(19.2% vs. 5.6%,P<0.001),调整OR为3.92;队列中性早熟使新发脊柱侧凸风险升高5.44倍。GnRHa治疗独立增加风险(HR=1.99,P=0.004),而维生素D补充使GnRHa治疗患者侧凸发生率降低51.5%(HR=0.43,P<0.001)。

要点

  • 性早熟患者脊柱侧凸患病率19.2%,显著高于对照组的5.6%。
  • GnRHa治疗独立增加脊柱侧凸风险(HR=1.99,P=0.004)。
  • 维生素D补充使GnRHa治疗患者侧凸发生率降低51.5%。

核心结论

  • 性早熟与GnRHa治疗协同增加脊柱侧凸风险,而维生素D联合治疗可减轻此效应。
  • 建议对开始GnRHa治疗的性早熟患者进行基线脊柱监测并补充维生素D。

研究设计与样本

  • 横断面分析纳入5605名参与者,回顾性队列纳入1575名个体。
  • 从医疗记录获取性早熟诊断、GnRHa治疗和维生素D补充数据。
  • 脊柱侧凸放射学定义为Cobb角≥10°。
  • 横断面分析采用Logistic回归,队列分析采用Cox回归评估关联。

主要发现

  • 横断面研究中,性早熟组脊柱侧凸患病率为19.2%,对照组为5.6%(P<0.001),调整OR为3.92。
  • 维生素D缺乏进一步增加脊柱侧凸风险(HR=2.04,P=0.003)。
  • 纵向队列中,性早熟与新发脊柱侧凸风险升高5.44倍相关。
  • GnRHa治疗独立增加脊柱侧凸风险(HR=1.99,P=0.004)。
  • 维生素D补充使GnRHa治疗患者脊柱侧凸发生率降低51.5%(HR=0.43,P<0.001)。

关键数值与推荐

  • 脊柱侧凸放射学定义:Cobb角≥10°。
  • 性早熟组脊柱侧凸患病率19.2%,对照组5.6%(P<0.001),调整OR=3.92。
  • 维生素D缺乏增加脊柱侧凸风险HR=2.04(P=0.003)。
  • 性早熟与新发脊柱侧凸风险HR=5.44。
  • GnRHa治疗增加脊柱侧凸风险HR=1.99(P=0.004)。

临床怎么用

  • 对性早熟患者应进行基线脊柱监测。
  • 对开始GnRHa治疗的患者建议补充维生素D。
  • 关注维生素D缺乏的性早熟患者脊柱侧凸风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Cross-sectional and retrospective cohort study. OBJECTIVE: This study aimed to investigate the impact of precocious puberty (PP) on scoliosis development and to evaluate the effects of gonadotropin-releasing hormone agonist (GnRHa) therapy and vitamin D (VitD) supplementation. SUMMARY OF BACKGROUND DATA: The effects of precocious puberty, GnRHa therapy, and VitD supplementation on scoliosis remain unclear. METHODS: The cross-sectional analysis included 5605 participants, while the retrospective cohort comprised 1575 individuals. Data on PP diagnosis, GnRHa therapy, VitD supplementation were obtained from medical records. Scoliosis was radiographically defined as a Cobb angle ≥10°. Logistic and Cox regression models were used in cross-sectional and cohort analyses, respectively, to assess the associations of PP and GnRHa therapy with scoliosis incidence. RESULTS: In the cross-sectional study, scoliosis prevalence was higher in the PP group compared with controls (19.2% vs. 5.6%, P <0.001), yielding an adjusted odds ratio (OR) of 3.92. Vitamin D deficiency further increased scoliosis risk (HR=2.04, P =0.003). In the longitudinal cohort, PP was associated with a 5.44-fold elevated risk of de novo scoliosis. GnRHa therapy independently increased scoliosis risk (HR=1.99, P =0.004). Conversely, VitD supplementation reduced scoliosis incidence by 51.5% among GnRHa-treated patients (HR=0.43, P <0.001). A U-shaped biphasic association was observed between estradiol levels and scoliosis risk (non-linear P <0.05). CONCLUSION: PP and GnRHa therapy synergistically increase scoliosis risk, whereas VitD co-therapy mitigates this effect. Baseline spinal surveillance and VitD supplementation are recommended for PP patients initiating GnRHa therapy. LEVEL OF EVIDENCE: 3.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Zhang S, Li X, Wu Y, et al. Precocious Puberty as a Significant Risk Factor for Scoliosis: A Retrospective Cohort Study Demonstrating Synergistic Effects of GnRHa Therapy and Protective Role of Vitamin D. Spine (Phila Pa 1976). 2026. PMID: 41944804. doi:10.1097/BRS.0000000000005681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。